Akzo Nobel appoints Dr. Jörg Spiekerkötter as CFO of Organon BioSciences N.V.
Arnhem, the Netherlands, October 26, 2006 — Akzo Nobel has appointed Dr. Jörg Spiekerkötter as Chief Financial Officer of its subsidiary Organon BioSciences N.V. He will officially take up the position on November 1, 2006. He will also be nominated for appointment as a member of the Board of Management of Organon BioSciences N.V.
Mr. Spiekerkötter (48) will join Organon BioSciences from Schering AG, where he was a member of the Executive Board responsible for Finance, Administration and Human Resources. His appointment marks an important landmark in the establishment of Akzo Nobel’s Pharma businesses as a separate company.
Commenting on the appointment, Akzo Nobel CEO Hans Wijers said: “We are very pleased to have appointed Jörg Spiekerkötter as CFO of Organon BioSciences. He has been working in the biopharma industry since 1991 and his specific expertise in finance, law and human resources complements the profile of CEO Toon Wilderbeek. Together they will form a strong team to lead Organon BioSciences into the next phase of its development.”
Mr. Spiekerkötter added: “I am looking forward to helping Organon BioSciences realize its ambitions as an independent company. I see Organon BioSciences as a highly professional business, driven by a clear ambition to deliver value from its excellent products and a healthy financial performance.”
A German citizen, Mr. Spiekerkötter has held a number of senior positions within the biopharma industry. He was head of Finance at Schering AG and was appointed head of Legal, Trademarks and Insurances at Hoechst Schering Agrevo GmbH. A graduate of the Universities of Bielefeld, Lausanne and Freiburg, Mr. Spiekerkötter holds a doctorate degree in Law.